Mark Iandolo Mar. 23, 2016, 1:02pm


WASHINGTON (Legal Newsline) — The Federal Trade Commission (FTC) has approved, after a public comment period ended, a final order settling charges that U.S. Renal Care Inc.’s $640 million acquisition of competitor DSI Renal from parent company Dialysis Parent LLC would be anti-competitive.

U.S. Renal Care is a national kidney-dialysis chain. Rangers Renal Holdings LP, its parent company, and Dialysis Parent LLC must divest three DSI Renal outpatient dialysis clinics in Laredo to a company called Satellite Healthcare Inc.

The FTC approved the final order by a vote of 4-0.

Organizations in this Story

U.S. Federal Trade Commission
600 Pennsylvania Ave NW
Washington, DC 20580

Get notified the next time we write about U.S. Federal Trade Commission !

More News